Taysha Gene Therapies annual return on equity
2021
2022
2023
2024
2025
Taysha Gene Therapies Return on Equity (ROE) Growth & History (TSHA)
Taysha Gene Therapies's return on equity was −68.45% for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −68.45% | +53.49 pp |
| 2024 | 2024-12-31 | −121.94% | +172.10 pp |
| 2023 | 2023-12-31 | −294.04% | +50.63 pp |
| 2022 | 2022-12-31 | −344.67% | −243.99 pp |
| 2021 | 2021-12-31 | −100.68% | — |
Taysha Gene Therapies quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −15.57% | +2.13 pp |
| Q1 2026 | 2026-03-31 | −18.48% | +15.53 pp |
| Q4 2025 | 2025-12-31 | −11.96% | +11.48 pp |
| Q3 2025 | 2025-09-30 | −14.00% | +11.83 pp |
| Q2 2025 | 2025-06-30 | −17.70% | +8.03 pp |
| Q1 2025 | 2025-03-31 | −34.02% | +3.35 pp |
| Q4 2024 | 2024-12-31 | −23.43% | −393.19 pp |
| Q3 2024 | 2024-09-30 | −25.83% | — |
| Q2 2024 | 2024-06-30 | −25.72% | — |
| Q1 2024 | 2024-03-31 | −37.37% | — |
| Q4 2023 | 2023-12-31 | 369.76% | +1315.14 pp |
| Q4 2022 | 2022-12-31 | −945.38% | −902.64 pp |
| Q3 2022 | 2022-09-30 | −122.78% | −91.46 pp |
| Q2 2022 | 2022-06-30 | −81.90% | −61.91 pp |
| Q1 2022 | 2022-03-31 | −68.87% | −55.36 pp |
| Q4 2021 | 2021-12-31 | −42.74% | −35.68 pp |
| Q3 2021 | 2021-09-30 | −31.32% | −20.07 pp |
| Q2 2021 | 2021-06-30 | −19.99% | — |
| Q1 2021 | 2021-03-31 | −13.51% | — |
| Q4 2020 | 2020-12-31 | −7.06% | — |
| Q3 2020 | 2020-09-30 | −11.25% | — |
Taysha Gene Therapies return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Taysha Gene Therapies's return on equity increased from −100.68% to −68.45%, a change of +32.23 percentage points. The latest reported quarter, Q2 2026, shows −15.57%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗